Compare NXL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | CLGN |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Israel |
| Employees | 7 | N/A |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 18.4M |
| IPO Year | N/A | 2015 |
| Metric | NXL | CLGN |
|---|---|---|
| Price | $0.40 | $0.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 208.5K | 63.0K |
| Earning Date | 03-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.28 | $1,596.12 |
| Revenue Next Year | $185.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.50 |
| 52 Week High | $2.57 | $4.98 |
| Indicator | NXL | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 35.46 |
| Support Level | $0.37 | $0.50 |
| Resistance Level | $0.62 | $0.73 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 8.79 | 48.94 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.